Cargando…

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model

INTRODUCTION: Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors. OBJECTIVE: To evaluate the ability of ande...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Genmin, Pine, Polly, Leeds, Janet M., DeGuzman, Francis, Pratikhya, Pratikhya, Lin, Joyce, Malinowski, John, Hollenbach, Stanley J., Curnutte, John T., Conley, Pamela B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874076/ https://www.ncbi.nlm.nih.gov/pubmed/29590221 http://dx.doi.org/10.1371/journal.pone.0195122

Ejemplares similares

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Cerebral infarction following administration of andexanet alfa for anticoagulant reversal in a patient with traumatic acute subdural hematoma
por: Nagai, Arata, et al.
Publicado: (2023)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

How will UK hospitals use andexanet alfa? A review of local protocols
por: Glancy, Paula, et al.
Publicado: (2023)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan B, et al.
Publicado: (2021)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
por: Singer, Adam J., et al.
Publicado: (2023)

Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital
por: Sobolewski, Kristine A., et al.
Publicado: (2021)

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
por: Ansell, Jack E., et al.
Publicado: (2017)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Grifonin-1: A Small HIV-1 Entry Inhibitor Derived from the Algal Lectin, Griffithsin
por: Micewicz, Ewa D., et al.
Publicado: (2010)

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage
por: Troyer, Camille, et al.
Publicado: (2022)

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy
por: Galli, Mattia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s3miv2rv3vt5ispvlc7hpt9eps